REMAP: Response Evaluation in Metastatic Renal Cell Cancer (mRCC) using 18F-FDG PET/MRI

Purpose: Size change is used on computed tomography (CT) to assess treatment response in metastatic renal cell cancer (mRCC) but has limitations that functional imaging using 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging (18F-FDG PET/MRI) may address. This exploratory study aimed to assess the feasibility of 18F-FDG PET/MRI in mRCC to assess disease activity and heterogeneity.

Source: Clinical Oncology - December 21, 2023 Category: Radiology Authors: T. Manickavasagar, C. Kelly-Morland, S. Rudman, D. Crawley, G. Cook, V. Goh Source Type: research